blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4135837

EP4135837 - METHODS FOR TREATING A COMPLEMENT MEDIATED DISORDER CAUSED BY VIRUSES [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  25.04.2024
Database last updated on 24.01.2025
FormerRequest for examination was made
Status updated on  20.01.2023
FormerThe international publication has been made
Status updated on  22.10.2021
Formerunknown
Status updated on  12.05.2021
Most recent event   Tooltip18.01.2025New entry: Decision on request for further processing 
Applicant(s)For all designated states
ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS
3, avenue Victoria
75004 Paris / FR
[2023/08]
Inventor(s)01 / BARR, Sharon
18 Matteo Court
Madison, CT 06443 / US
02 / DUNN, Derek
34 Spring St., Apt. 1
Somerville, MA 02143 / US
03 / GAO, Xiang
7 Franklins Way
Guilford, CT 06437 / US
04 / KAZANI, Shamsah, D.
148 Cyress St.
Watertown, MA 02472 / US
05 / MERCURI, Michele
45 W 3rd St., Apt. 519 S.
Boston, MA 02127 / US
06 / MONTELEONE, Jonathan
1332 Medfield Road
Raleigh, NC 27607 / US
07 / ORTIZ, Stephan
18 Ivy Road
Wellesley, MA 02482 / US
08 / ROTTINGHAUS, Scott, T.
45 Emerald Glen Lane
Salem, CT 06420 / US
09 / ZIMMERMANN, Martine
41 Q rue Schnapper
78100 Saint-Germain-en-Laye / FR
10 / ANNANE, Djillali
34 rue Delaporte
94700 Maisons-Alfort / FR
11 / FREMEAUX-BACCHI, Veronique
9 rue Raphael
92170 Vanves / FR
12 / PEFFAULT DE LATOUR, Regis
23 Boulevard Georges Seurat
92200 Neuilly-sur-Seine / FR
 [2023/08]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/08]
Application number, filing date21723594.416.04.2021
[2023/08]
WO2021US27636
Priority number, dateUS202063010905P16.04.2020         Original published format: US 202063010905 P
US202063014999P24.04.2020         Original published format: US 202063014999 P
US202063019050P01.05.2020         Original published format: US 202063019050 P
US202063020195P05.05.2020         Original published format: US 202063020195 P
US202063020286P05.05.2020         Original published format: US 202063020286 P
US202063033140P01.06.2020         Original published format: US 202063033140 P
US202063063538P10.08.2020         Original published format: US 202063063538 P
[2023/08]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021211940
Date:21.10.2021
Language:EN
[2021/42]
Type: A1 Application with search report 
No.:EP4135837
Date:22.02.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 21.10.2021 takes the place of the publication of the European patent application.
[2023/08]
Search report(s)International search report - published on:EP21.10.2021
ClassificationIPC:A61P11/00, A61P31/12, A61P37/00, C07K16/18
[2023/08]
CPC:
A61P11/00 (EP); C07K16/18 (EP,US); A61K45/06 (US);
A61P31/12 (EP); A61P31/14 (US); A61P37/00 (EP);
G01N33/56983 (US); A61K2039/505 (EP); A61K2039/545 (EP);
C07K2317/24 (EP,US); C07K2317/76 (US); C07K2317/94 (EP);
G01N2469/20 (US); Y02A50/30 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/08]
TitleGerman:VERFAHREN ZUR BEHANDLUNG EINER KOMPLEMENTVERMITTELTEN VIRUSBEDINGTEN ERKRANKUNG[2023/08]
English:METHODS FOR TREATING A COMPLEMENT MEDIATED DISORDER CAUSED BY VIRUSES[2023/08]
French:MÉTHODES DE TRAITEMENT D'UN TROUBLE MÉDIÉ PAR LE COMPLÉMENT PROVOQUÉ PAR DES VIRUS[2023/08]
Entry into regional phase14.10.2022National basic fee paid 
14.10.2022Designation fee(s) paid 
14.10.2022Examination fee paid 
Examination procedure14.10.2022Examination requested  [2023/08]
14.10.2022Date on which the examining division has become responsible
27.06.2023Despatch of communication of loss of particular rights: Claims {1}
06.09.2023Amendment by applicant (claims and/or description)
24.04.2024Despatch of a communication from the examining division (Time limit: M06)
11.11.2024Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
13.01.2025Reply to a communication from the examining division
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
13.01.2025Request for further processing filed
13.01.2025Full payment received (date of receipt of payment)
Request granted
17.01.2025Decision despatched
06.09.2023Request for further processing filed
06.09.2023Full payment received (date of receipt of payment)
Request granted
12.09.2023Decision despatched
Fees paidRenewal fee
27.04.2023Renewal fee patent year 03
29.04.2024Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]  - F DIURNO ET AL, "Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, IT, vol. 24, no. 7, doi:10.26355/eurrev_202004_20875, ISSN 1128-3602, (20200401), pages 4040 - 4047, URL: https://www.europeanreview.org/wp/wp-content/uploads/4040-4047.pdf, XP055809596 [X] 1,29,30,36 * discussion * [I] 2-18,20-28,32,33,35,37,38,40

DOI:   http://dx.doi.org/10.26355/eurrev_202004_20875
 [T]  - Alexion Pharmaceuticals, "Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia: NCT04369469", Clinical Trials, (20200430), URL: https://clinicaltrials.gov/ct2/show/NCT04369469, (20210706), XP055821529 [T] * the whole document *
 [T]  - Alexion Pharmaceuticals, "SOLIRIS (Eculizumab) Treatment of Participants With COVID-19 (NCT04355494)", Clinical Trials, US, (20200421), URL: https://clinicaltrials.gov/ct2/show/NCT04355494, (20210706), XP055821530 [T] * the whole document *
 [A]  - MARKS WILLIAM H. ET AL, "Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: A randomized trial", AMERICAN JOURNAL OF TRANSPLANTATION, DK, vol. 19, no. 10, doi:10.1111/ajt.15364, ISSN 1600-6135, (20191001), pages 2876 - 2888, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790671/pdf/AJT-19-2876.pdf, XP055821549 [A] 1-40 * table 1 *

DOI:   http://dx.doi.org/10.1111/ajt.15364
 [A]  - MAGRO CYNTHIA ET AL, "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases", TRANSLATIONAL RESEARCH, ELSEVIER, AMSTERDAM, NL, vol. 220, doi:10.1016/J.TRSL.2020.04.007, ISSN 1931-5244, (20200415), pages 1 - 13, (20200415), XP086179509 [A] 1-40 * figure 4 *

DOI:   http://dx.doi.org/10.1016/j.trsl.2020.04.007
 [T]  - RAGHUNANDAN SHARMILA ET AL, "Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome", FRONTIERS IN PEDIATRICS, (20201229), vol. 8, doi:10.3389/fped.2020.616731, XP055809594

DOI:   http://dx.doi.org/10.3389/fped.2020.616731
 [T]  - SMITH KEISHA ET AL, "A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study p", TRIALS, GB, vol. 21, no. 1, doi:10.1186/s13063-020-04548-z, ISSN 1745-6215, (20200713), page 639, URL: http://link.springer.com/article/10.1186/s13063-020-04548-z/fulltext.html, XP055821551

DOI:   http://dx.doi.org/10.1186/s13063-020-04548-z
by applicantWO9404678
 WO9425591
 WO9529697
 US6005079
 US6074642
 US6355245
 US2007116710
 WO2007106585
 WO2008069889
 US7390786
 EP2089058
 EP0758904
 US7999081
 WO2011137395
 US8088376
 US8241628
 US8883158
 US9011852
 US9079949
 EP2563813
 WO2015134894
 US9371378
 EP2359834
 EP3124029
 EP2824111
 US9718880
 US9725504
 US9732149
 WO2019014360
 US10450370
    - GRALINSKI et al., mEio, (20181009), vol. 9, no. 5
    - JIANG et al., Emerg Microbes Infect, (20180424), vol. 7, no. 1, page 77
    - SUN et al., ,4n J Respir Cell Mol Biol, (20130800), vol. 49, no. 2, pages 221 - 30
    - TODOROVSKA et al., J Immunol Methods, (20010000), vol. 248, no. 1, pages 47 - 66
    - HUDSONKORTT, J Immunol Methods, (19990000), vol. 231, no. 1, pages 177 - 189
    - POLJAK, Structure, (19940000), vol. 2, no. 12, pages 1121 - 1123
    - RONDONMARASCO, Annual Review of Microbiology, (19970000), vol. 51, pages 257 - 283
    - MUYLDERMANS et al., Trends Eiochem Sci, (20010000), vol. 26, pages 230 - 235
    - NUTTALL et al., Czar Pharm Biotech, (20000000), vol. 1, pages 253 - 263
    - REICHMANN et al., J Immunol Meth, (19990000), vol. 231, pages 25 - 38
    - MULLER-EBERHARD, Ann Rev Biochem, (19880000), vol. 57, pages 321 - 347
    - MEDICUS et al., J Exp Med, (19760000), vol. 144, pages 1076 - 1093
    - FEARON et al., J Exp Med, (19750000), vol. 142, pages 856 - 863
    - ISENMAN et al., J Immunol, (19800000), vol. 124, no. 1, pages 326 - 331
    - SCHREIBER et al., Proc Natl Acad Sci USA, (19780000), vol. 75, pages 3948 - 3952
    - SISSONS et al., Proc Natl Acad Sci USA, (19800000), vol. 77, pages 559 - 562
    - COOPER et al., J Exp Med, (19700000), vol. 132, pages 775 - 793
    - HAVILAND et al., J Immunol., (19910000), vol. 146, pages 362 - 368
    - FREDSLUND et al., Nat Immunol, (20080000), vol. 9, no. 7, pages 753 - 760
    - MINT AMAN, J Immunol, (19970000), vol. 119, pages 1597 - 1602
    - WETSELKOLB, J Immunol, (19820000), vol. 128, pages 2209 - 2216
    - YAMAMOTOGEWURZ, J Immunol, (19780000), vol. 120, page 2008
    - DAMERAU et al., Molec Immunol, (19890000), vol. 26, pages 1133 - 1142
    - HOLERS et al., Immunological Reviews, (20080000), vol. 223, pages 300 - 316
    - CAMPBELL et al., Circulation, (20200602), vol. 141, no. 22, pages 1739 - 1741
    - VOLOKHINA, Blood, (20150709), vol. 126, no. 2, pages 278 - 279
    - DIJKMAN et al., J Formos Med Assoc, (20090400), vol. 108, no. 4, pages 270 - 9
    - DE WIT et al., Nat Rev Microbiol, (20160800), vol. 14, no. 8, pages 523 - 34
    - AL-TAWFIQ et al., Int J Infect Dis, (20140300), vol. 20, pages 42 - 6
    - DYALL et al., Antimicrob Agents Chemother, (20140800), vol. 58, no. 8, pages 4885 - 93
    - MODJARRAD et al., Lancet Infect Dis, (20190900), vol. 19, no. 9, pages 1013 - 1022
    - CHANNAPPANAVAR et al., Semin Immunopathol, (20170700), vol. 39, no. 5, pages 529 - 539
    - GU et al., J Exp Med., (20050801), vol. 202, no. 3, pages 415 - 24
    - NICHOLLS et al., Lancet, (20030524), vol. 361, no. 9371, pages 1773 - 8
    - NG et al., Am J Pathol, (20160300), vol. 186, no. 3, pages 652 - 8
    - MENACHERY et al., Nat Med, (20151200), vol. 21, no. 12, pages 1508 - 1
    - HUI et al., Curr Opin Pulm Med, (20140500), vol. 20, no. 3, pages 233 - 41
    - CABEZA et al., J Virol, (20180715), vol. 92, no. 14, pages e00633 - 18
    - GUNN et al., Virology, (20180200), vol. 515, pages 250 - 260
    - SCHINDLER et al., Blood, (19900000), vol. 76, pages 1631 - 1638
    - SUN et al., Am. J. Respir. Cell. Mol. Biol., (20130000), vol. 49, pages 221 - 230
    - THURMAN et al., Arthritis Rheumatol, (20171100), vol. 69, no. 11, pages 2102 - 2113
    - ZELEK et al., Mol Immunol, (20191000), vol. 114, pages 341 - 352
    - HILLMEN et al., N Engl J Med, (20040000), vol. 350, no. 6, pages 552 - 9
    - ROTHER et al., Nature Biotechnology, (20070000), vol. 25, no. 11, pages 1256 - 1264
    - HILLMEN et al., N Engl J Med, (20060000), vol. 355, no. 12, pages 1233 - 1243
    - ZUBER et al., Nature Reviews Nephrology, (20120000), vol. 8, pages 643 - 657
    - WHISS, Curr Opin Investig Drugs, (20020000), vol. 3, no. 6, pages 870 - 7
    - PATEL et al., Drugs Today (Bare, (20050000), vol. 41, no. 3, pages 165 - 70
    - THOMAS et al., Mol Immunol, (19960000), vol. 33, no. 17-18, pages 1389 - 14011
    - KEEFE, Nature Reviews Drug Discovery, (20100700), vol. 9, pages 537 - 550
    - PENABAD et al., Lupus, (20141000), vol. 23, no. 12, pages 1324 - 6
    - MOONGKARNDI et al., Immunobiol, (19820000), vol. 162, page 397
    - MOONGKAT11DI et al., Immunobiol, (19830000), vol. 165, page 323
    - WARDZVAIFLER, J Clin Invest, (19710000), vol. 50, no. 3, pages 606 - 16
    - WURZNER et al., Complement Inflamm, (19910000), vol. 8, pages 328 - 340
    - JONSSON et al., Biotechniques, (19910000), vol. 11, pages 620 - 627
    - CHOTHIA et al., Nature, (19890000), vol. 342, pages 877 - 883
    - DALL'ACQUA et al., J Biol Chem, (20060000), vol. 281, pages 23514 - 23524
    - HINTON et al., J Biol Chem, (20040000), vol. 279, pages 6213 - 6216
    - HINTON et al., J Immunol, (20060000), vol. 176, pages 346 - 356
    - PETKOVA et al., Int In inunol, (20060000), vol. 18, no. 12, pages 1759 - 69
    - DATTA-MANNAN et al., J Biol Chem, (20070000), vol. 282, no. 3, pages 1709 - 1717
    - JOHNE et al., J Immunol Meth, (19930000), vol. 160, pages 191 - 198
    - JONSSON et al., Ann Biol Clin, (19930000), vol. 51, pages 19 - 26
    - EVANS et al., Mol Irnmunol, (19950000), vol. 32, no. 16, pages 1183 - 240
    - EVANS et al., Mol Immunol, (19950000), vol. 32, no. 16, pages 1183 - 95
    - BERGE et al., J Pharm Sci, (19770000), vol. 66, pages 1 - 19
    - "Protein Formulation and Delivery", MCNALLYHASTEDT, Drugs and the Pharmaceutical Sciences, CRC Press, (20070000), vol. 175
    - MATIS et al., "Complement-specific antibodies: designing novel anti-inflammatories", Nat Med, (19950000), vol. 1, doi:10.1038/nm0895-839, pages 839 - 842, XP037075548

DOI:   http://dx.doi.org/10.1038/nm0895-839
    - GRANGER et al., Circulation, (20030000), vol. 108, page 1184
    - HAVERICH et al., Ann Thorac Surg, (20060000), vol. 82, pages 486 - 492
    - TESTA et al., J Thorac Cardiovasc Surg, (20080000), vol. 136, no. 4, pages 884 - 893
    - JODELE et al., Biol Blood Marrow Transplant., (20160000), vol. 22, no. 2, pages 307 - 315
    - PEFFAULT DE LATOUR et al., Blood, (20150000), vol. 125, no. 5, pages 775 - 783
    - MARKS et al., Am J Transplant, (20190000), vol. 19, no. 10, pages 2876 - 2888
    - JOHNS HOPKINS UNIVERSITY, COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, (20200521), URL: worldwidewebcoronavirus.jhu.edu/map.html
    - GUAN et al., N Engl J Med, (20200000), vol. 382, pages 1708 - 1720
    - US CENTERS FOR DISEASE CONTROL AND PREVENTION, COVIDView: A weekly surveillance summary of U.S. COVID-19 Activity, key updates for week 16, ending April 18, 2020, (20200521), URL: worldwidewebcdc.gov/coronavirus/2019-ncov/covid-datalcovidview/index.html
    - "Sante Publique France Infection au nouveau Coronavirus (SARS-CoV-2), COVID-19", France et Monde, URL: worldwidewebsantepubliquefrance.fr/maladies-et-traumatismes/maladies-et-infections-respiratoires/infection-a-coronavirus/articles/infection-au-nouveau-coronavirus-sars-cov-2-covid-19-france-et-monde
    - HUANG et al., Lancet, (20200000), vol. 395, pages 1054 - 1062
    - PANDYA et al., Am J Respir Cell Mol Biol, (20140000), vol. 51, pages 467 - 473
    - WANG et al., Emerg Microbes Infect, (20150000), vol. 4, page e28
    - GRALINSKI et al., "Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis", mBio, (20180000), vol. 9, pages e01753 - 01718
    - SUN et al., Am J Respir Cell Mol Biol, (20130000), vol. 49, pages 221 - 230
    - JIANG et al., Emerg Microbes Infect, (20180000), vol. 7, page 77
    - SUN et al., Clin Infect Dis, (20150000), vol. 60, pages 586 - 595
    - PANG et al., Clin Chem, (20060000), vol. 52, pages 421 - 429
    - OHTA et al., Microbiol Immunol, (20110000), vol. 55, pages 191 - 198
    - BERDAL et al., J Infect, (20110000), vol. 63, pages 308 - 316
    - LEGENDRE et al., N Engl J Med, (20130000), vol. 368, pages 2169 - 2181
    - PITTOCK et al., N Engl J Med, (20190000), vol. 381, pages 614 - 625
    - HOWARD et al., Lancet Neurol, (20170000), vol. 16, pages 976 - 986
    - MERLE et al., Front Immunol, (20150000), vol. 6, page 257
    - MORGAN et al., Immunol Rev, (20160000), vol. 274, pages 141 - 15
    - DIURNO et al., Eur Rev Med Pharmacol Sci, (20200000), vol. 24, pages 4040 - 4047
    - PITTS TC, "A preliminary update to the Soliris to Stop Immune Mediated Death in Covid-19 (SOLID-C19) compassionate use study", Hudson Medical, (20200000), URL: worldwidewebhudsonmedical.com/articles/soliris-stop-death-covid-19
    - GATTINONI et al., Intensive Care Med, (20200000), vol. 46, pages 854 - 887
    - RICHARDSON et al., JAMA, (20200526), vol. 323, no. 20, pages 2052 - 2059
    - CAO B et al., N Engl J Med, (20200507), vol. 382, no. 19, pages 1787 - 1799
    - GREIN et al., N Engl J Med, (20200611), vol. 382, no. 24, pages 2327 - 2336
    - GOLDMAN et al., N Engl J Med, (20201105), vol. 383, no. 19, pages 1827 - 1837
    - SUN et al., Clin. Infect Dis, (20150000), vol. 60, pages 586 - 595
    - KESHARI et al., Proceedings of the National Academy of Sciences, (20170000), vol. 114, pages E6390 - E6399
    - BAKKER et al., Annals of Intensive Care, (20130000), vol. 3, page 12
    - MAGRO et al., Transl Res, (20200600), vol. 220, pages 1 - 13
    - SOCIE et al., Br J Haematol, (20190000), vol. 185, pages 297 - 310
    - CUCINOTTA DVANELLI M., Acta Biomed, (20200000), vol. 91, pages 157 - 160
    - RISITANO et al., "Complement as a target in COVID-19?", Nat Rev Immunol, (20200600), vol. 20, no. 6, doi:10.1038/s41577-020-0320-7, pages 343 - 344, XP037153297

DOI:   http://dx.doi.org/10.1038/s41577-020-0320-7
    - GRALINSKI et al., mBio, (20180000), vol. 9, no. 5
    - MAGRO et al., Transl Res, (20200000), no. 20, pages 1931 - 5244
    - DIURNO et al., European Review for Medical and Pharmacological Sciences, (20200000), no. 24, pages 4030 - 4037
    - BIKDELI et al., J Am Coll Cardiol, (20200616), vol. 75, no. 23, pages 2950 - 2973
    - CONNORS JMLEVY JH, "COVID-19 and Its Implications for Thrombosis and Anticoagulation", Blood, (20200604), vol. 135, no. 23, pages 2033 - 2040
 WO2015US19225
 WO2018US41661
 EP20180746529
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.